News about "Eli Lilly and Company "

Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India

Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.

Eli Lilly And Company | 14/05/2026 | By News Bureau

Roche Receives CE Mark for Blood-Based Alzheimer's Diagnostic Test

Roche receives CE Mark approval for Elecsys pTau217, a blood-based Alzheimer’s diagnostic test developed with Eli Lilly, aimed at enabling earlier and less invasive detection of amyloid pathology in patients with cognitive decline.

Eli Lilly And Company | 13/05/2026 | By News Bureau

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Eli Lilly And Company | 13/05/2026 | By News Bureau

Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.

Eli Lilly And Company | 06/05/2026 | By News Bureau |  116

Eli Lilly and Company to Acquire Ajax Therapeutics to Expand Blood Cancer Pipeline

Eli Lilly and Company to acquire Ajax Therapeutics, advancing its blood cancer pipeline with AJ1-11095, a Phase 1 JAK2 inhibitor targeting myelofibrosis and polycythemia vera, with potential for improved disease control.

Eli Lilly And Company | 28/04/2026 | By News Bureau

Amazon Pharmacy to Deliver Foundayo Same-Day, Expanding Access to Eli Lilly's New GLP-1 Pill

Amazon Pharmacy now offers Eli Lilly’s GLP-1 pill Foundayo with real-time availability, transparent pricing from USD 1/day with insurance, USD 5/day cash, and automatic manufacturer-sponsored coupons—soon via in-office kiosks within minutes.

Eli Lilly And Company | 09/04/2026 | By News Bureau |  166

Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration

Fauna Bio has achieved a target designation milestone in its obesity discovery collaboration, advancing a novel target identified through its Convergence AI platform.

Eli Lilly And Company | 20/03/2026 | By News Bureau

Zuellig Pharma Acquires Rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea

Zuellig Pharma has acquired rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea, expanding its ownership of the men’s health drug across 11 Asian markets.

Eli Lilly And Company | 16/03/2026 | By News Bureau |  209

Lilly Positions India as Global Manufacturing Hub Amid Mounjaro Demand

Eli Lilly and Company is moving to position India as a strategic global manufacturing and export hub, supported by strong demand for its blockbuster diabetes and obesity therapy Mounjaro. A senior executive said the company is advancing plans to integrate India more deeply into its worldwide supply chain through contract manufacturing partnerships.

Eli Lilly And Company | 18/02/2026 | By Darshana |  268

Lilly's Retevmo Shows Significant Benefit in Early-Stage RET+ Lung Cancer in Phase III Trial

LIBRETTO-432 study demonstrates statistically significant improvement in event-free survival as adjuvant therapy for stage II–IIIA RET fusion-positive NSCLC.

Eli Lilly And Company | 17/02/2026 | By News Bureau |  222